(Q53148481)

English

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

scientific article published on 23 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Heather Landau

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Neeta Pandit-Taskar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hani Hassoun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Alex Lesokhin

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Nikoletta Lendvai

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Pamela Drullinsky

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Philip Schulman

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Suresh Jhanwar

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Elizabeth Hoover

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Christina Bello

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Elyn Riedel

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Stephen D Nimer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Raymond L Comenzo

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

23 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

53

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

275-281

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Bortezomib: an effective agent in extramedullary disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Reliability of measuring iliac crest level in the standing and sitting position using a new measurement device.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.606943

21 January 2018

Identifiers

10.3109/10428194.2011.606943

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

release_cgoxkecz5zesvn4h5o3erkrd4u

1 reference

https://api.fatcat.wiki/v0/release/cgoxkecz5zesvn4h5o3erkrd4u

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21824051%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53148481&oldid=1837968137"